Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPT-11 with Carboplatin in Glioblastoma Multiforme
NCT00010036Phase 2Completed
- Sponsor
- NYU Langone Health
- Start
- May 1999
- Primary completion
- Oct 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan in glioblastoma multiforme (GBM), sponsored by NYU Langone Health. Primary endpoint: Maximum Tolerated Dose. Started May 1999; status: completed.
02
Drugs
irinotecan
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00010036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00010036.